Bosentan decreased pulmonary vascular resistance in inoperable CTEPH

Bosentan decreased pulmonary vascular resistance in inoperable CTEPH

Bosentan decreased pulmonary vascular resistance in inoperable chronIc thromboembolic pulmonary hypertension (CTEPH): Bosentan is a drug which is effective for primary pulmonary hypertension. Xavier Jaïs 1, Andrea M D’Armini, Pavel Jansa, Adam Torbicki, Marion Delcroix, Hossein A Ghofrani, Marius M Hoeper, Irene M Lang, Eckhard Mayer, Joanna Pepke-Zaba, Loïc Perchenet, Adele Morganti, Gérald Simonneau and Lewis J Rubin, the Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group published the results of BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a Randomized, Placebo-Controlled Trial in the of Journal of American College of Cardiology [1]. 157 patients participated in the trial and they were randomized to bosentan or placebo for 16 weeks. Pulmonary vascular resistance (PVR) was reduced and the cardiac index improved in the bosentan treated group, but the 6-minute walk distance did not improve. Further trials are needed to assess whether the improved pulmonary vascular resistance will translate into long term clinical benefits. Bosentan treatment was well-tolerated and appears promising for patients with chronic thromboembolic pulmonary hypertension.

Reference

1. Xavier Jaïs, Andrea M D’Armini, Pavel Jansa, Adam Torbicki, Marion Delcroix, Hossein A Ghofrani, Marius M Hoeper, Irene M Lang, Eckhard Mayer, Joanna Pepke-Zaba, Loïc Perchenet, Adele Morganti, Gérald Simonneau, Lewis J Rubin, Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008 Dec 16;52(25):2127-34.